<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03849027</url>
  </required_header>
  <id_info>
    <org_study_id>MOUNTAIN-PAIN</org_study_id>
    <nct_id>NCT03849027</nct_id>
  </id_info>
  <brief_title>MethOxyflUraNe at moderaTe High AltItudes for PAIN Management</brief_title>
  <acronym>MOUNTAIN-PAIN</acronym>
  <official_title>MethOxyflUraNe at moderaTe High AltItudes for PAIN Management: A Randomised, Double-blind, Cross-over Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cape Town</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cape Town</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomised, double-blind, cross-over study to assess the analgesic effect of methoxyflurane
      at moderate high altitudes in a wilderness field setting.

      Phase IV, randomised, double-blind, cross-over clinical trial to evaluate the analgesic
      effect of methoxyflurane at moderate high altitudes in a wilderness field setting, in 24
      healthy volunteers
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary outcome: To assess the analgesic efficacy of inhaled methoxyflurane at moderate high
      altitudes in a wilderness setting.

      Secondary outcomes: To assess the comparative safety and adverse events with inhaled
      methoxyflurane at moderate high altitudes in a wilderness setting.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2019</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>randomised, controlled, cross-over</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Analgesic effect</measure>
    <time_frame>Up to 3 weeks</time_frame>
    <description>Percentage change in analgesic effect between methoxyflurane inhalation at sea level (ALT 0) and 2250m (ALT 2; moderate high altitude).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and adverse events</measure>
    <time_frame>Up to 3 weeks</time_frame>
    <description>Comparative safety and adverse events with inhaled methoxyflurane at moderate high altitudes in a wilderness setting</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Methoxyflurane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled methoxyflurane once-off dose of 3 ml will be administered via the inhaler at each dosing visit .
Inhaled methoxyflurane will be administered using the disposable field inhaler device (Penthrop®).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Methoxyflurane</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>The sham inhaler will have one droplet of methoxyflurane applied to the outer surface, but no drug in the vaporization chamber to give off the prominent odour with no analgesic effect, partially blinding the participants to the test</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methoxyflurane</intervention_name>
    <description>Inhaled methoxyflurane will be administered using the disposable field inhaler device (Penthrop®) according to the recommended dosing schedule.</description>
    <arm_group_label>Methoxyflurane</arm_group_label>
    <other_name>Penthrop</other_name>
    <other_name>Penthrox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The sham inhaler will have one droplet of methoxyflurane applied to the outer surface, but no drug in the vaporization chamber to give off the prominent odour with no analgesic effect, partially blinding the participants to the test.</description>
    <arm_group_label>Sham Methoxyflurane</arm_group_label>
    <other_name>Sham methoxyflurane</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female between 18 and 65 years of age (inclusive).

          2. Able to provide informed consent and comply with study-related procedures

        Exclusion Criteria:

          1. History of diabetes

          2. Renal or hepatic disease or impairment (defined as a value exceeding the maximum
             reference range)

          3. Chronic or nociplastic pain

          4. Chronic fatigue syndrome

          5. Chronic/regular use of analgesic medications

          6. Personal or familial history of malignant hyperthermia

          7. Personal or familial history of anaesthesia-induced rhabdomyolysis

          8. Personal history of anaesthesia volatile-induced hepatitis or drug induced liver
             injury

          9. Recent volatile anaesthesia (within 6 months)

         10. History of significant altitude-related illness

         11. Significant underlying medical condition which precludes gentle exercise at moderate
             high altitude (&lt;2500 m ASL) as determined by the investigators

         12. Hypersensitivity to Penthrox/Penthrop®, methoxyflurane or any fluorinated anaesthetic.

         13. Concurrent treatment with CYP 2A6 or CYP 2E1 enzyme inducers (such as: phenobarbital,
             rifampicin, alcohol or isoniazid)

         14. Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ross Hofmeyr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cape Town</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ross Hofmeyr</last_name>
    <phone>+2721 650 4957</phone>
    <email>ross.hofmeyr@uct.ac.za</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicky Kramer</last_name>
    <phone>+2721 650 4196</phone>
    <email>nicky.kramer@uct.ac.za</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Cape Town Department of Anaesthesia &amp; Perioperative Medicine</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <contact>
      <last_name>Ross Hofmeyr</last_name>
      <phone>+2721 650 4957</phone>
      <email>ross.hofmeyr@uct.ac.za</email>
    </contact>
    <contact_backup>
      <last_name>Nicky Kramer</last_name>
      <phone>+2721 650 4196</phone>
      <email>nicky.kramer@uct.ac.za</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 18, 2019</study_first_submitted>
  <study_first_submitted_qc>February 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2019</study_first_posted>
  <last_update_submitted>February 19, 2019</last_update_submitted>
  <last_update_submitted_qc>February 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cape Town</investigator_affiliation>
    <investigator_full_name>Ross Hofmeyr</investigator_full_name>
    <investigator_title>Prof</investigator_title>
  </responsible_party>
  <keyword>altitude</keyword>
  <keyword>analgesia</keyword>
  <keyword>methoxyflurane</keyword>
  <keyword>wilderness medicine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methoxyflurane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

